|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Pharmacyclics |
| Information provided by: | Pharmacyclics |
| ClinicalTrials.gov Identifier: | NCT00080041 |
Purpose
The primary purpose of this study is to evaluate the safety, toxicities, and dosage for investigational drug Motexafin Gadolinium administered with docetaxel to patients with advanced solid tumors. Secondly, tumor response to the combined treatment will be evaluated.
| Condition | Intervention | Phase |
|
Breast Neoplasms Ovarian Neoplasms Prostatic Neoplasms Lung Neoplasms |
Drug: Motexafin Gadolinium Injection |
Phase I |
| Genetics Home Reference related topics: | breast cancer |
| MedlinePlus related topics: | Breast Cancer Cancer Lung Cancer Ovarian Cancer Prostate Cancer |
| Drug Information available for: | Docetaxel Motexafin gadolinium Motexafin |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
| Official Title: | Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Administered at 3-Week Intervals for Advanced Solid Tumors |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Laboratory Values of:
and
Contacts and Locations
More Information
| Study ID Numbers: | PCYC-0214 |
| First Received: | March 22, 2004 |
| Last Updated: | May 11, 2007 |
| ClinicalTrials.gov Identifier: | NCT00080041 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|